MedTrace Logo

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis

NCT03387423 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1459

Last updated 2024-10-21

Study results available
· View outcomes & findings →

Summary

This non-interventional study aims to identify key factors that are driving treatment decisions by rheumatologists in the treatment of rheumatoid arthritis (RA) patients starting treatment with Tofacitinib in a real world setting.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Tofacitinib

Patients who are started on Tofacitinib treatment according to the drug label

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-02
Primary Completion
2023-07-17
Completion
2023-07-17

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03387423 on ClinicalTrials.gov